Just to be clear, although there are a couple of strategies to try and work around AMGN's Enbrel patent #8,063,182, I am quite certain Protalix won't be able to do so.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.